Corbus Pharmaceuticals Holdings Inc
NASDAQ:CRBP
Balance Sheet
Balance Sheet Decomposition
Corbus Pharmaceuticals Holdings Inc
Current Assets | 23.5m |
Cash & Short-Term Investments | 20.9m |
Other Current Assets | 2.6m |
Non-Current Assets | 4.7m |
PP&E | 4m |
Other Non-Current Assets | 690.2k |
Current Liabilities | 31.9m |
Accounts Payable | 3.2m |
Accrued Liabilities | 12.5m |
Other Current Liabilities | 16.2m |
Non-Current Liabilities | 3.3m |
Other Non-Current Liabilities | 3.3m |
Balance Sheet
Corbus Pharmaceuticals Holdings Inc
Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||||
Cash & Cash Equivalents |
6
|
12
|
15
|
63
|
42
|
32
|
85
|
25
|
17
|
14
|
|
Cash |
0
|
0
|
1
|
0
|
1
|
1
|
2
|
7
|
4
|
4
|
|
Cash Equivalents |
6
|
12
|
14
|
62
|
41
|
31
|
84
|
18
|
13
|
10
|
|
Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
73
|
42
|
7
|
|
Total Receivables |
0
|
0
|
1
|
0
|
0
|
3
|
3
|
0
|
0
|
0
|
|
Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
3
|
2
|
0
|
0
|
0
|
|
Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
|
Other Current Assets |
0
|
0
|
1
|
3
|
3
|
4
|
4
|
3
|
1
|
3
|
|
Total Current Assets |
7
|
13
|
17
|
66
|
44
|
38
|
92
|
100
|
60
|
24
|
|
PP&E Net |
0
|
0
|
0
|
1
|
3
|
11
|
9
|
7
|
6
|
4
|
|
PP&E Gross |
0
|
0
|
0
|
1
|
3
|
11
|
9
|
7
|
6
|
4
|
|
Accumulated Depreciation |
0
|
0
|
0
|
0
|
1
|
1
|
2
|
2
|
3
|
4
|
|
Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
|
Total Assets |
7
N/A
|
13
+95%
|
18
+39%
|
67
+274%
|
47
-30%
|
49
+4%
|
102
+108%
|
108
+5%
|
66
-38%
|
28
-57%
|
|
Liabilities | |||||||||||
Accounts Payable |
0
|
1
|
3
|
3
|
6
|
11
|
7
|
2
|
2
|
3
|
|
Accrued Liabilities |
0
|
1
|
3
|
5
|
10
|
23
|
23
|
11
|
7
|
12
|
|
Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
4
|
3
|
16
|
|
Other Current Liabilities |
0
|
2
|
2
|
0
|
2
|
0
|
1
|
0
|
0
|
0
|
|
Total Current Liabilities |
1
|
4
|
9
|
8
|
18
|
35
|
32
|
17
|
13
|
32
|
|
Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
18
|
16
|
16
|
0
|
|
Other Liabilities |
0
|
0
|
0
|
1
|
1
|
8
|
7
|
6
|
5
|
3
|
|
Total Liabilities |
1
N/A
|
4
+457%
|
9
+131%
|
9
+2%
|
20
+112%
|
43
+121%
|
57
+33%
|
39
-32%
|
33
-14%
|
35
+6%
|
|
Equity | |||||||||||
Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Retained Earnings |
4
|
13
|
33
|
66
|
121
|
193
|
304
|
350
|
392
|
437
|
|
Additional Paid In Capital |
10
|
22
|
42
|
124
|
149
|
199
|
349
|
419
|
425
|
430
|
|
Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Total Equity |
6
N/A
|
9
+53%
|
9
-1%
|
58
+549%
|
28
-52%
|
6
-77%
|
45
+631%
|
69
+53%
|
33
-52%
|
7
N/A
|
|
Total Liabilities & Equity |
7
N/A
|
13
+95%
|
18
+39%
|
67
+274%
|
47
-30%
|
49
+4%
|
102
+108%
|
108
+5%
|
66
-38%
|
28
-57%
|
|
Shares Outstanding | |||||||||||
Common Shares Outstanding |
1
|
1
|
2
|
2
|
2
|
2
|
3
|
4
|
4
|
4
|